rauwolfia alkaloids
Small moleculeapproved
Approved
Jan 28, 1954
Alseroxylon is a norepinephrine reuptake inhibitor that has been investigated in the treatment of hypertension and angina pectoris and as a sedative in psychoses. It was at one time approved for use in the United States, but has since been discontinued. — Wikipedia
Clinical trial activity
5 trials · 6 clinical orgs · 19 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
1
Earliest trial started Apr 1, 1966 (NCT00000484)
Timeline
1800s
- Jan 1, 1800
Evidence of US Marketing
1950s
- Jun 1, 1953
3M — First NDA Organization
- Jun 1, 1953
3M — NDA Organization
- Jan 28, 1954
Earliest FDA Approval
- Jan 28, 1954
Bowman Pharms — NDA Secondary Org
1960s
- Jan 1, 1966
Earliest Phase 3 Sponsor(trial)
1970s
- Jul 11, 1972
Solvay — Marketing Organization
- Nov 8, 1972
Watson Pharmaceuticals — Marketing Organization
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Adrenergic receptor alphaANTAGONIST
Adrenergic receptor alpha antagonist
- Norepinephrine transporterANTAGONIST
SC6A2 antagonist
Approval history
- approvedJan 28, 1954
- approvedJan 1, 1800
Chemistry & pharmacology
Loading structure…
SMILES
CCC1C2CC3C4N(C)c5ccccc5C45CC(C2[C@H]5O)N3C1O- Mol. weight
- 326.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaAlseroxylon ↗
- NCATSH192N84N1G ↗
- ChEMBLCHEMBL5314404 ↗
- ChEMBLCHEMBL3559672 ↗
- ChEMBLCHEMBL2105617 ↗
- ChEMBLCHEMBL1201454 ↗
Also known as
- (5ar,6s,8s,10s,11s,11as,12ar,13r)-5-methyl-5a,6,8,9,10,11,11a,12-octahydro-5h-6,10:11,12a-dimethanoindolo[3,2-b]quinolizine-8,13-diol
- (5ar,6s,8s,10s,11s,11as,12ar,13r)-5-methyl-5a,6,8,9,10,11,11a,12-octahydro-5h-6,10:11,12a-dimethanoindolo[3,2-b]quinolizine-8,13-diol
- ajmalin
- ajmalin
- ajmalin
- ajmaline
- ajmaline
- ajmaline
- ajmaline
- ajmaline
- ajmaline
- (+)-ajmaline
- (+)-ajmaline
- (+)-ajmaline
- ajmaline hcl
- ajmaline hydrochloride
- ajmaline hydrochloride
- ajmaline hydrochloride
- ajmaline hydrochloride
- ajmaline hydrochloride
- ajmaline hydrochloride
- alkaloids, rauwolfia
- alseroxylon
- alseroxylon
- alseroxylon
- alseroxylon
- alseroxylon
- aritmina
- cardiorythmine
- gilurytmal
- hiwolfia
- hyserpin
- koglucoid
- raugalline
- rauserpin
- rauserpin
- rautensin
- rautensin
- rauverid
- rauvolfia serpentina root
- rauwiloid
- rauwiloid
- rauwiloid
- rauwiloid
- rauwolfia
- rauwolfia
- rauwolfia alkaloids
- rauwolfia alkaloids
- rauwolfia alkaloids, whole root
- rauwolfia root
- rauwolfia root
- rauwolfia serpentina
- rauwolfia serpentina
- rauwolfia serpentina
- rauwolfia serpentina alseroxylon
- rauwolfia serpentina root
- rauwolfia serpentina root
- rauwolfia serpentina root
- rauwolfia serpentina root
- snakeroot
- wolfina
- wolfina
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06595745 | N/A | May 28, 2024 | Emory University, Michigan State University |
| NCT02933437 | Phase 2 | May 26, 2017 | University of London |
| NCT02641431 | N/A | Nov 1, 2015 | University of Milan |
| NCT00702117 | Phase 4 | Jun 1, 2008 | University of Barcelona |
| NCT00000484 | Phase 3 | Apr 1, 1966 | National Heart, Lung, and Blood Institute (NHLBI) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Michigan State University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 1 | 1 | 1966 |
| University of Barcelona | Academic/Hospital | 1 | 1 | 1 | 2008 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Milan | Academic/Hospital | 1 | 1 | 1 | 2015 |
6 organizations
Page 1 / 1
Marketing (19)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| 3M | For profit | NDA | Jun 1, 1953 |
| Apothecon | For profit | NDA2 | — |
| Bausch Health Companies | For profit | NDA2 | — |
| Bowman Pharms | For profit | NDA2 | Jan 28, 1954 |
| Bundy | For profit | NDA2 | — |
| Ferndale Laboratories, Inc. | For profit | NDA2 | — |
| Forest Laboratories | For profit | NDA2 | — |
| Halsey | For profit | MKTG | — |
| Impax Laboratories | For profit | NDA2 | — |
| Lannett Company, Inc. | For profit | NDA2 | — |
| Mylan | For profit | MKTG | — |
| Novartis | For profit | NDA2 | — |
| PHYS PRODS VA | For profit | NDA2 | — |
| Panray Corp. | For profit | NDA2 | — |
| Puracap Pharmaceutical | For profit | MKTG | — |
| Solvay | For profit | MKTG | Jul 11, 1972 |
| Tablicaps | For profit | MKTG | — |
| Teva | For profit | NDA2 | — |
| Watson Pharmaceuticals | For profit | MKTG | Nov 8, 1972 |